DEVINCENZI ROBERT THOMAS

UTI Director DeVincenzi purchases 10,000 shares for $253,990.88 across two transactions at $25.39–$25.40, raising stake 7.9%.

Director Robert Thomas DeVincenzi executed 2 separate purchases totaling 10,000 shares for $253,990.88 at a blended average price of $25.40 on 2025-08-12, increasing his holdings from 126,765 to 136,765 shares (+7.9%). The purchases occurred at prices near the current market level ($25.50) but represent a material position addition when the stock is trading -29.0% from its 52-week high and -20.1% over the prior 30 days. His cross-ticker track record shows 2 prior sells with a 90-day well-timed rate of 0.00%, and his 2 prior sales at UTI in November 2024 yielded positive 90-day returns (+4.2% and +2.0%), indicating neither was well-timed. The company reports robust fundamentals with $204.3M quarterly revenue, +20.6% annual growth, and a P/E of 21.98, providing a backdrop of operational strength that contextualizes the discretionary buy decision.

Director DeVincenzi sells 150,000 shares (55.1% of holdings) at blended $25.46; stock at 52-week high of $26.04

Director Robert Thomas DeVincenzi executed two separate sales totaling 150,000 shares for $3,818,252.05 on 2024-11-25, reducing his holdings from 272,452 to 122,452 shares. The sale occurred at a blended average price of $25.46, near the 52-week high of $26.04, during a period of strong momentum (30-day change: +55.1%, 90-day change: +50.3%). The company's fundamentals show robust growth with annual revenue growth of +45.0% and a market cap of $1,401,259,714.68, though the P/E of 47.35 reflects premium valuation. This represents a material reduction of 55.1% of his pre-transaction position, executed at elevated price levels following significant recent gains.